A test using plasma biomarkers of endothelial dysfunction—specifically the ratio of the anti- and pro-angiogenic factors, soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF), respectively—is now commercially available. The gene discussed is PGF; the disease is endothelial dysfunction.